⚠️ DISCLAIMER: This tool is for educational and research purposes only. It does NOT constitute financial advice.

STOKS Value Investing Scanner

WATCH Nippon Shinyaku Co., Ltd. (4516.T)

Healthcare · Drug Manufacturers - Specialty & Generic · JPX · Japan
56
Final Score ?
-17.4%
Margin of Safety ?
71
Quality Score ?
¥3,549
Current Price ?
¥239.2B
Market Cap ?

Key Metrics

Pe Ratio ?
8.05
Forward Pe ?
8.64
Pb Ratio ?
0.81
Ev Ebitda ?
4.03
Roe ?
11.5%
Gross Margin ?
65.3%
Operating Margin ?
25.1%
Net Margin ?
17.5%
Dividend Yield ?
350.0%
Debt To Equity ?
0.86
Current Ratio ?
4.66

📈 Trend Charts

Revenue Trend
EPS Trend
Net Income Trend
Free Cash Flow Trend

Intrinsic Value Estimates

Low ?
¥2,418
Base ?
¥3,022
High ?
¥3,627

Pipeline Stage Details

Stage A — Hard Filters ✅

Pe Ratio
8.05
Eps Positive Years
4.00
Eps Lookback
4.00
Fcf Positive Years
4.00
Fcf Lookback
4.00
Debt To Equity
0.86
Current Ratio
4.66
Dilution Cagr
0.00

Stage B — Quality Score: 71/100

Stage C — Cyclicality: LOW

Normalized EPS
¥411.69

Stage F — Final Score Breakdown

ComponentWeighted Score
Valuation 3.0
Earnings Quality 17.7
Balance Sheet 15.0
Stability 12.0
Moat Proxies 7.9

Top Drivers

  1. High quality business (score 71/100): above-average returns on capital and reliable earnings generation.
  2. Low P/E of 8.0x — classic Graham deep-value territory. The market is pricing in pessimism, yet the business continues to generate positive earnings.
  3. Solid ROIC of 13.3% — above the 12% threshold, indicating the business creates genuine economic value for shareholders.
  4. Conservative leverage: D/E ratio of 0.86x is well within Graham's maximum of 1.0x, reducing insolvency risk.
  5. Strong free cash flow generation — the company converts earnings into real cash effectively, supporting dividends, buybacks, and debt reduction.

Top Risks

  1. No significant risks identified in this analysis.

Financial History ?

Year Revenue ? Gross Profit ? Operating Income ? Net Income ? EPS ?
2023 ¥144.2B ¥88.2B ¥30.1B ¥22.8B ¥338.70
2024 ¥148.3B ¥98.0B ¥33.3B ¥25.9B ¥383.82
2025 ¥160.2B ¥109.1B ¥35.5B ¥32.6B ¥483.26
2026 ¥170.8B ¥113.3B ¥35.5B ¥29.7B ¥441.00

Cash Flow History ?

Year Operating CF ? CapEx ? Free Cash Flow ?
2022 N/A N/A N/A
2023 ¥26.2B ¥-11.7B ¥14.4B
2024 ¥16.3B ¥-9.6B ¥6.6B
2025 ¥36.1B ¥-34.8B ¥1.3B
2026 ¥27.2B ¥-3.8B ¥23.4B

What is it?
Graham & Buffett say